Expression frequency of single markers within the cohort and histopathologic subgroups
. | All, % (no./no. total) . | DLBCL, % (no./no. total)* . | BL/BLL, % (no./no. total) . | Others, % (no./no. total)† . | P‡ . |
|---|---|---|---|---|---|
| CD3 | 0 (0/89) | 0 (0/41) | 0 (0/27) | 0 (0/21) | — |
| CD10 | 49 (43/88) | 41 (17/41) | 81 (22/27) | 20 (4/20) | < .001 |
| CD20 | 75 (67/89) | 98 (40/41) | 89 (24/27) | 14 (3/21) | < .001 |
| BCL-6 | 65 (57/88) | 83 (34/41) | 78 (21/27) | 10 (2/20) | < .001 |
| CD38 | 48 (42/88) | 29 (12/41) | 52 (14/27) | 80 (16/20) | < .001 |
| MUM1/IRF4 | 45 (34/75) | 29 (10/35) | 36 (8/22) | 89 (16/18) | < .001 |
| CD138/Syn-1 | 15 (12/80) | 3 (1/36) | 4 (1/26) | 56 (10/18) | < .001 |
| LMP-1 | 20 (17/83) | 20 (8/41) | 12 (3/26) | 38 (6/16) | .126 |
| BCL-2 | 20 (18/89) | 29 (12/41) | 15 (4/27) | 14 (2/21) | .131 |
. | All, % (no./no. total) . | DLBCL, % (no./no. total)* . | BL/BLL, % (no./no. total) . | Others, % (no./no. total)† . | P‡ . |
|---|---|---|---|---|---|
| CD3 | 0 (0/89) | 0 (0/41) | 0 (0/27) | 0 (0/21) | — |
| CD10 | 49 (43/88) | 41 (17/41) | 81 (22/27) | 20 (4/20) | < .001 |
| CD20 | 75 (67/89) | 98 (40/41) | 89 (24/27) | 14 (3/21) | < .001 |
| BCL-6 | 65 (57/88) | 83 (34/41) | 78 (21/27) | 10 (2/20) | < .001 |
| CD38 | 48 (42/88) | 29 (12/41) | 52 (14/27) | 80 (16/20) | < .001 |
| MUM1/IRF4 | 45 (34/75) | 29 (10/35) | 36 (8/22) | 89 (16/18) | < .001 |
| CD138/Syn-1 | 15 (12/80) | 3 (1/36) | 4 (1/26) | 56 (10/18) | < .001 |
| LMP-1 | 20 (17/83) | 20 (8/41) | 12 (3/26) | 38 (6/16) | .126 |
| BCL-2 | 20 (18/89) | 29 (12/41) | 15 (4/27) | 14 (2/21) | .131 |
Total number tested was 89; for DLBCL, n = 41; for BL/BLL, n = 27; and for others, n = 21.
DLBCL indicates diffuse large B-cell lymphoma; BL/BLL, Burkitt and Burkitt-like lymphoma; and —, not applicable.
From the DLBCL, immunoblastic and plasmablastic lymphoma were excluded.
This group included in 6 immunoblastic, 11 plasmablastic lymphoma, 1 undifferentiated plasmocytoma, and 3 cases that displayed morphologic features of primary effusion lymphomas.
Chi-square test, comparing frequencies of markers in the 3 histopathologic subgroups.